Health
Question mark over effectiveness of Pfizer-BioNTech COVID-19 vaccine in obese people – BioPharma-Reporter.com
New data may have serious implications for the development of vaccination strategies for COVID-19, particularly in individuals with obesity.
A study by a team of researchers based at Istituti Fisioterapici Ospitalieri (IFO) in Rome, Italy, aimed to analyse the antibody response following two doses of the Pfizer/BioNTech COVID-19 vaccine, BNT162B2, in 248 healthcare workers. They also looked to evaluate how the antibody titer in those participants changed in relation to age, gender and body mass index (BMI).
Of the cohort studied, 158 were women (63.7%) and 90 were men (36.3%). The average age was 47 years, with the range going from 23…
-
Noosa News13 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News14 hours agoMotorcyclist dies in crash with truck
-
Noosa News15 hours agoSomerville House investigating after teachers’ dossier on students leaked
-
General20 hours agoSmall-town cleaner finds himself in legal battle with EnduroShield over product packaging